ARTICLE | Financial News
Adlai Nortye raises $50M series B
June 29, 2018 6:09 PM UTC
Chinese immunotherapy company Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) raised over $50 million in a series B round led by YuanMing Capital. Matrix Partners China, DT Capital Partners and Yahui Precision Medicine Fund also participated.
Adlai Nortye has in-licensed two cancer immunotherapy candidates, including Reolysin pelareorep and E7046 (AN0025)...
BCIQ Target Profiles
Prostaglandin E2 (PGE2) receptor EP4 subtype (Prostanoid EP4 receptor) (PTGER4)